Report Detail
Global Adalimumab Market Growth 2019-2024
- RnM2772463 |
- 15 January, 2019 |
- Global |
- 138 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
According to this study, over the next five years the Adalimumab market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2017. In particular, this report presents the global market share (sales and revenue) of key companies in Adalimumab business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Adalimumab market by product type, application, key manufacturers and key regions and countries.
This study considers the Adalimumab value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2013 to 2018, in Section 2.3; and forecast to 2024 in section 11.7.
Adalimumab
Adalimumab Biosimilar
Segmentation by application: breakdown data from 2013 to 2018, in Section 2.4; and forecast to 2024 in section 11.8.
Adults
Children
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Adalimumab consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2024.
To understand the structure of Adalimumab market by identifying its various subsegments.
Focuses on the key global Adalimumab manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Adalimumab with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Adalimumab submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2018-2023 Global Adalimumab Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Adalimumab Consumption 2013-2023
- 2.1.2 Adalimumab Consumption CAGR by Region
- 2.2 Adalimumab Segment by Type
- 2.2.1 Adalimumab
- 2.2.2 Adalimumab Biosimilar
- 2.3 Adalimumab Consumption by Type
- 2.3.1 Global Adalimumab Consumption Market Share by Type (2013-2018)
- 2.3.2 Global Adalimumab Revenue and Market Share by Type (2013-2018)
- 2.3.3 Global Adalimumab Sale Price by Type (2013-2018)
- 2.4 Adalimumab Segment by Application
- 2.4.1 Adults
- 2.4.2 Children
- 2.5 Adalimumab Consumption by Application
- 2.5.1 Global Adalimumab Consumption Market Share by Application (2013-2018)
- 2.5.2 Global Adalimumab Value and Market Share by Application (2013-2018)
- 2.5.3 Global Adalimumab Sale Price by Application (2013-2018)
3 Global Adalimumab by Players
- 3.1 Global Adalimumab Sales Market Share by Players
- 3.1.1 Global Adalimumab Sales by Players (2016-2018)
- 3.1.2 Global Adalimumab Sales Market Share by Players (2016-2018)
- 3.2 Global Adalimumab Revenue Market Share by Players
- 3.2.1 Global Adalimumab Revenue by Players (2016-2018)
- 3.2.2 Global Adalimumab Revenue Market Share by Players (2016-2018)
- 3.3 Global Adalimumab Sale Price by Players
- 3.4 Global Adalimumab Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Adalimumab Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Adalimumab Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Adalimumab by Regions
- 4.1 Adalimumab by Regions
- 4.1.1 Global Adalimumab Consumption by Regions
- 4.1.2 Global Adalimumab Value by Regions
- 4.2 Americas Adalimumab Consumption Growth
- 4.3 APAC Adalimumab Consumption Growth
- 4.4 Europe Adalimumab Consumption Growth
- 4.5 Middle East & Africa Adalimumab Consumption Growth
5 Americas
- 5.1 Americas Adalimumab Consumption by Countries
- 5.1.1 Americas Adalimumab Consumption by Countries (2013-2018)
- 5.1.2 Americas Adalimumab Value by Countries (2013-2018)
- 5.2 Americas Adalimumab Consumption by Type
- 5.3 Americas Adalimumab Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Adalimumab Consumption by Countries
- 6.1.1 APAC Adalimumab Consumption by Countries (2013-2018)
- 6.1.2 APAC Adalimumab Value by Countries (2013-2018)
- 6.2 APAC Adalimumab Consumption by Type
- 6.3 APAC Adalimumab Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Adalimumab by Countries
- 7.1.1 Europe Adalimumab Consumption by Countries (2013-2018)
- 7.1.2 Europe Adalimumab Value by Countries (2013-2018)
- 7.2 Europe Adalimumab Consumption by Type
- 7.3 Europe Adalimumab Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Adalimumab by Countries
- 8.1.1 Middle East & Africa Adalimumab Consumption by Countries (2013-2018)
- 8.1.2 Middle East & Africa Adalimumab Value by Countries (2013-2018)
- 8.2 Middle East & Africa Adalimumab Consumption by Type
- 8.3 Middle East & Africa Adalimumab Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.2 Adalimumab Distributors
- 10.3 Adalimumab Customer
11 Global Adalimumab Market Forecast
- 11.1 Global Adalimumab Consumption Forecast (2018-2023)
- 11.2 Global Adalimumab Forecast by Regions
- 11.2.1 Global Adalimumab Forecast by Regions (2018-2023)
- 11.2.2 Global Adalimumab Value Forecast by Regions (2018-2023)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Adalimumab Forecast by Type
- 11.8 Global Adalimumab Forecast by Application
12 Key Players Analysis
- 12.1 AbbVie
- 12.1.1 Company Details
- 12.1.2 Adalimumab Product Offered
- 12.1.3 AbbVie Adalimumab Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.1.4 Main Business Overview
- 12.1.5 AbbVie News
- 12.2 Amgen
- 12.2.1 Company Details
- 12.2.2 Adalimumab Product Offered
- 12.2.3 Amgen Adalimumab Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.2.4 Main Business Overview
- 12.2.5 Amgen News
- 12.3 Sandoz
- 12.3.1 Company Details
- 12.3.2 Adalimumab Product Offered
- 12.3.3 Sandoz Adalimumab Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.3.4 Main Business Overview
- 12.3.5 Sandoz News
- 12.4 Boehringer Ingelheim
- 12.4.1 Company Details
- 12.4.2 Adalimumab Product Offered
- 12.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.4.4 Main Business Overview
- 12.4.5 Boehringer Ingelheim News
- 12.5 Mylan
- 12.5.1 Company Details
- 12.5.2 Adalimumab Product Offered
- 12.5.3 Mylan Adalimumab Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.5.4 Main Business Overview
- 12.5.5 Mylan News
- 12.6 Biogen
- 12.6.1 Company Details
- 12.6.2 Adalimumab Product Offered
- 12.6.3 Biogen Adalimumab Sales, Revenue, Price and Gross Margin (2016-2018)
- 12.6.4 Main Business Overview
- 12.6.5 Biogen News
...
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Adalimumab . Industry analysis & Market Report on Adalimumab is a syndicated market report, published as Global Adalimumab Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Adalimumab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
